The amino acid leucine turns up mitochondrial power by slowing protein cleanup — in cells and roundworms

Leucine — an essential amino acid you get from protein foods — just gained a surprising job description. In a study from the University of Cologne published in Nature Cell Biology, researchers found that leucine slows the cell’s protein-cleanup machinery in a way that leaves more mitochondrial energy equipment on the job. The catch, flagged by the study’s own lead author: that cleanup also removes damaged parts, so boosting output this way could cost the cell later.

What did the study find?

The team, led by Prof. Thorsten Hoppe with first author Dr. Qiaochu Li, showed that leucine reduces the activity of SEL1L, a quality-control protein that flags outer-mitochondrial-membrane proteins for degradation. With less flagging, fewer energy-making proteins get hauled away — more stay in place to support respiration.

The biology held across models. In C. elegans roundworms, defects in leucine metabolism disrupted mitochondrial function and were linked to fertility problems. In human lung cancer cells, leucine-related mutations helped tumors survive — a reminder that the same pathway operates in very different contexts.

The catch, straight from the lead scientist

Here’s what makes this study stand out: the researchers volunteered the warning themselves. SEL1L doesn’t just clear useful proteins — it clears damaged ones. Suppressing cleanup to keep output high could let damaged machinery accumulate, harming long-term cellular health. Whether the benefit-risk balance is tunable — more power now without paying later — is completely unknown.

The work was funded through Germany’s Excellence Strategy (CECAD), the German Research Foundation, an ERC Advanced Grant, and the Humboldt Foundation.

What this doesn’t mean for your diet

This is a mechanism study in cells and roundworms — not a reason to mega-dose leucine. Human relevance and any therapeutic window are unknown, and the cancer-cell finding (leucine-related mutations helping tumors survive) is a genuine reason for caution, not enthusiasm, about cranking this pathway.

The real takeaway is conceptual: mitochondrial output isn’t just about making more machinery — it’s about the balance between building and clearing. Therapies that nudge that balance will need to reckon with both sides.

Where the evidence stands

• Established: Leucine is an essential amino acid; SEL1L is a mitochondrial quality-control protein that flags damaged proteins for degradation.
• Preliminary: The leucine→SEL1L→respiration mechanism — demonstrated in cell lines and roundworms; fertility and tumor-survival links observed in those models.
• Absent: Human relevance, any therapeutic window, and whether the benefit/risk balance is tunable.